MDM2 and melanoma: Melanomas of non-responder patients had significantly more fully inactivating mutations of senescence-inducing cell cycle genes (CDKN2A/B/C; CDKN1A/B; RB1; TP53; JAK1/2/3) or ≥ 3fold amplifications of genes promoting cell cycle progression (CCND1/2/3; CDK4/6; CCNE1; MDM2/4; MYC) than the biopsy material of melanomas from responder patients (Fig. 10c, Supplementary Fig. 13 and 14a, b).